301 related articles for article (PubMed ID: 27363678)
1. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
6. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
[TBL] [Abstract][Full Text] [Related]
7. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.
Satelli A; Batth I; Brownlee Z; Mitra A; Zhou S; Noh H; Rojas CR; Li H; Meng QH; Li S
Oncotarget; 2017 Jul; 8(30):49329-49337. PubMed ID: 28521303
[TBL] [Abstract][Full Text] [Related]
8. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
[TBL] [Abstract][Full Text] [Related]
9. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
11. Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis.
Kong D; Zhang W; Yang Z; Li G; Cheng S; Zhang K; Feng L
Oncoimmunology; 2021 Jun; 10(1):1938476. PubMed ID: 34211802
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Strati A; Koutsodontis G; Papaxoinis G; Angelidis I; Zavridou M; Economopoulou P; Kotsantis I; Avgeris M; Mazel M; Perisanidis C; Sasaki C; Alix-Panabières C; Lianidou E; Psyrri A
Ann Oncol; 2017 Aug; 28(8):1923-1933. PubMed ID: 28838214
[TBL] [Abstract][Full Text] [Related]
13. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
15. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
[TBL] [Abstract][Full Text] [Related]
16. Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Shim KH; Kwon JE; Park SG; Choo SH; Kim SJ; Kim SI
Urol Oncol; 2021 May; 39(5):298.e13-298.e20. PubMed ID: 33712343
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
Cells; 2024 May; 13(9):. PubMed ID: 38727318
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of cell surface vimentin positive circulating tumor cells as a prognostic biomarker for stage III/IV colorectal cancer.
Yu J; Yang M; Peng T; Liu Y; Cao Y
Sci Rep; 2023 Nov; 13(1):18791. PubMed ID: 37914786
[TBL] [Abstract][Full Text] [Related]
20. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
